Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Liabilities (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Total Liabilities data on record, last reported at $31.0 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 89.55% year-over-year to $31.0 million; the TTM value through Sep 2025 reached $31.0 million, up 89.55%, while the annual FY2024 figure was $21.5 million, 104.38% up from the prior year.
  • Total Liabilities reached $31.0 million in Q3 2025 per DNTH's latest filing, up from $23.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $216.4 million in Q1 2022 and bottomed at $4.0 million in Q2 2023.
  • Average Total Liabilities over 4 years is $31.5 million, with a median of $16.3 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: tumbled 97.24% in 2023, then surged 166.26% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $9.5 million in 2022, then increased by 11.43% to $10.5 million in 2023, then skyrocketed by 104.38% to $21.5 million in 2024, then soared by 43.94% to $31.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $31.0 million in Q3 2025, $23.0 million in Q2 2025, and $20.0 million in Q1 2025.